Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Four-Arm, Parallel-Group, Proof of Concept, and Dose-Finding Adaptive Phase 2a/2b Study to Investigate the Safety, Tolerability and Efficacy and Effect on Quality of Life of Human Recombinant Alkaline Phosphatase in the Treatment of Patients With Sepsis-Associated Acute Kidney Injury

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Four-Arm, Parallel-Group, Proof of Concept, and Dose-Finding Adaptive Phase 2a/2b Study to Investigate the Safety, Tolerability and Efficacy and Effect on Quality of Life of Human Recombinant Alkaline Phosphatase in the Treatment of Patients With Sepsis-Associated Acute Kidney Injury

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ilofotase alfa (Primary)
  • Indications Acute kidney injury
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Acronyms STOP-AKI
  • Sponsors AM-Pharma

Most Recent Events

  • 24 Oct 2018 Results published in the JAMA: the Journal of the American Medical Association
  • 24 Oct 2018 Primary endpoint has not been met. (Measured creatinine clearance (based on urine volume and creatinine concentrations)), according to an AM-Pharma media release.
  • 24 Oct 2018 According to an AM-Pharma media release, results from this study will be presented at the European Society of Intensive Care Medicine (ESICM) and at the American Society of Nephrology Kidney Week (Oct 2018).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top